Overview

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Status:
Completed
Trial end date:
2009-02-17
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically and to assess the impact of pneumococcal conjugate vaccine on pneumococcal and H. influenzae nasopharyngeal carriage compared to control group receiving meningococcal conjugate vaccine (GSK134612). This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00370318).
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Acetaminophen
Antipyretics
Heptavalent Pneumococcal Conjugate Vaccine
Vaccines